Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11329
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grossmann, Mathis | en |
dc.contributor.author | Zajac, Jeffrey D | en |
dc.date.accessioned | 2015-05-16T00:55:08Z | |
dc.date.available | 2015-05-16T00:55:08Z | |
dc.date.issued | 2011-09-01 | en |
dc.identifier.citation | Endocrinology and Metabolism Clinics of North America; 40(3): 655-71, x | en |
dc.identifier.govdoc | 21889727 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11329 | en |
dc.description.abstract | Androgen deprivation therapy (ADT) is a major component of the contemporary management of prostate cancer. ADT's use is increasing rapidly. The side effects of this therapy include loss of bone mass and fractures, increase in fat mass, and worsening of insulin resistance, the metabolic syndrome, diabetes and cardiovascular risk, and anemia and loss of muscle. Neuropsychological and sexual symptoms are common. The impact of these side effects is often overlooked or underestimated in decisions about prostate cancer therapy. This review surveys the data relating to the side effects of ADT and provides recommendations regarding their minimization and management. | en |
dc.language.iso | en | en |
dc.subject.other | Androgen Antagonists.adverse effects.therapeutic use | en |
dc.subject.other | Animals | en |
dc.subject.other | Antineoplastic Agents, Hormonal.adverse effects.therapeutic use | en |
dc.subject.other | Carcinoma.drug therapy.epidemiology.metabolism.physiopathology | en |
dc.subject.other | Cardiovascular Physiological Phenomena.drug effects | en |
dc.subject.other | Dietary Supplements.utilization | en |
dc.subject.other | Drug-Related Side Effects and Adverse Reactions.epidemiology.therapy | en |
dc.subject.other | Humans | en |
dc.subject.other | Life Style | en |
dc.subject.other | Male | en |
dc.subject.other | Prostatic Neoplasms.drug therapy.epidemiology.metabolism.physiopathology | en |
dc.title | Management of side effects of androgen deprivation therapy. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Endocrinology and metabolism clinics of North America | en |
dc.identifier.affiliation | Department of Medicine Austin Health/Northern Health, University of Melbourne, Heidelberg, Victoria 3084, Australia | en |
dc.identifier.doi | 10.1016/j.ecl.2011.05.004 | en |
dc.description.pages | 655-71, x | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/21889727 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Grossmann, Mathis | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.